The usually recommended dose of Pazufloxacin Injections in most infections is 500 mg twice a day administered as an I.V. infusion over 30-60 minutes. Depending on age, symptoms and severity of infection, the dose of the drug may be reduced to 300 mg twice a day.

Pazufloxacin has good antibacterial activity against variety of clinical isolates. The MICs at which 90% of the isolates were inhibited (MIC90s) of pazufloxacin were 0.2 to 0.39 ug/ml for Staphylococcus aureus and Staphylococcus epidermidis, including methicillin-resistant strains.5 Pazufloxacin has similar or 2-fold greater activity than other quinolones, against the following Enterobacteriaceae (MIC90 ≤ 0.25 ug/ml): Escherichia coli, Klebsiella, Enterobacter, Hafnia, Citrobacter, Proteus, Providencia, Serratia, Shigella, Salmonella, Aeromonas and Yersinia. Against P. aeruginosa, pazufloxacin shows more potent activity than tosufloxacin, norfloxacin and ofloxacin. Against clinical isolates of methicillin-resistant Staphylococcus aureus and P. aeruginosa, pazufloxacin has an MIC90 of 0.39 ug/ml and an MIC90 of 0.78 ug/ml respectively. MIC90 for clinical isolates of H. influenzae is ≤ 0.013 ug/l.